Related Experiment Video

Updated: Aug 18, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
06:26

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization

Published on: January 24, 2025

[Colloid drug delivery systems: a response to therapeutic expectations arising from biotechnological advances?]

D Goldstein1, G Lambert, Fr Puisieux

  • 1Département de pharmacie galénique, Ecole de pharmacie, Université hébraïque de Jérusalem, Ein Kherem Campus, PO BOX 12065, 91120 Jérusalem, Israel.

Annales Pharmaceutiques Francaises
|April 2, 2005
PubMed

Insights

Monoclonal antibodies are revolutionizing cancer therapy by targeting tumor antigens. Coupling these antibodies with colloid vectors enhances drug delivery, improving cancer treatment efficacy and reducing side effects.

Area of Science:

  • Biotechnology
  • Immunology
  • Oncology

Context:

  • Cancer progression is linked to over-expressed tumor antigens.
  • Monoclonal antibodies offer targeted therapeutic potential.
  • Advances in biotechnology enable novel drug delivery systems.

Purpose:

  • To discuss the synergy between biotechnology and molecular pharmotechnology for cancer therapy.
  • To explore the use of antibody-conjugated colloid vectors for targeted cancer treatment.

Summary:

  • Researchers are coupling monoclonal antibodies with colloid vectors (liposomes, nanoparticles) to deliver cytotoxic compounds directly to cancer cells.
  • This targeted approach aims to maximize efficacy against cancerous cells while minimizing damage to healthy tissues.
  • The integration of biotechnology and pharmotechnology opens new therapeutic avenues for cancer.

Impact:

  • Enhanced specificity in cancer treatment.
  • Potential for reduced systemic toxicity of chemotherapeutics.
  • Development of innovative targeted cancer therapies.

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Related Concept Videos

Oral Drug Delivery Systems: Introduction01:23

Oral Drug Delivery Systems: Introduction

Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...